BHST

Investor Moves

Name	Value	Action	Change	Price	Current Price
Ken GriffinCitadel Advisors $64k14.8k shares TrimQ1 2026 $16k $4.34 $3.86

News

newsfilecorp.comBioHarvest Sciences to Present at the 2026 BIO International Conventionnewsfilecorp.comJun 18

proactiveinvestors.comBioHarvest Sciences and Tate & Lyle expand sweetener development programproactiveinvestors.comMay 19

newsfilecorp.comTate & Lyle Expands Collaboration with BioHarvest Sciences to Accelerate Next-Generation Sweetener Innovationnewsfilecorp.comMay 18

seekingalpha.comBioHarvest Sciences Inc. (BHST) Q1 2026 Earnings Call Transcriptseekingalpha.comMay 14

marketbeat.comBioHarvest Sciences Q1 Earnings Call Highlightsmarketbeat.comMay 14

Trade BHST

About BioHarvest Sciences Inc. Common Stock

BioHarvest Sciences Inc. functions as a biotechnology firm with operations segmented into Nutraceuticals and Pharmaceuticals. A key innovation is its proprietary botanical synthesis platform technology, which allows for the cultivation of active ingredients found within plant enzymes or cells. The company harnesses this advanced technology to craft evidence-based and clinically validated therapeutic products for both its nutraceutical and pharmaceutical offerings. Beyond its own development, it also provides contract development and manufacturing services. Its product portfolio includes various wellness items, notably VINIA, a dietary supplement derived from red grape cells, which delivers the full spectrum of polyphenols naturally present in red grapes. The company conducts business in Israel and the United States, with its corporate base in Vancouver, Canada.

CEO: Ilan Sobel
IPO Date: Jan 8, 2021

Market Data

Open: $3.37
High: $3.37
Low: $3.26
Volume: 2.2K
Avg Volume: 28.9K
52W High: $12.80
52W Low: $3.02

Valuation

Market Cap: $56M
Enterprise Value: $54M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-9.6M
Revenue: $35M
Net Income: $-11M
Cash: $23M
Debt: $14M

Events

EarningsAug 10

EPS est. -0.13